Summary
Elevance Health, Inc. (then Anthem, Inc.) filed an 8-K on May 5, 2020, to report the successful closing of a significant notes offering. The company raised approximately $2.483 billion in net proceeds from the sale of $400 million of 2.375% senior notes due 2025, $1.1 billion of 2.250% senior notes due 2030, and $1 billion of 3.125% senior notes due 2050. These proceeds are intended for general corporate purposes, including working capital, debt repayment, share repurchases, and potential acquisitions. This offering demonstrates the company's ability to access capital markets effectively to support its strategic objectives and financial flexibility. Investors should note the specific terms of the notes, including interest rates, maturity dates, and redemption provisions. The filing also outlines conditions under which the company would be required to offer to repurchase the notes in the event of a change of control coupled with a credit rating downgrade.
Key Highlights
- 1Closed a notes offering raising approximately $2.483 billion in net proceeds.
- 2Issued three series of senior notes: $400M of 2.375% Notes due 2025, $1.1B of 2.250% Notes due 2030, and $1B of 3.125% Notes due 2050.
- 3Proceeds are earmarked for working capital, general corporate purposes, debt repayment, share repurchases, and funding acquisitions.
- 4The new notes were issued under the company's existing indenture, managed by The Bank of New York Mellon Trust Company, N.A.
- 5Detailed information on interest payment dates, accrual methods, and events of default is provided.
- 6The company retains the right to redeem the notes under specific conditions before maturity (Par Call Dates) or at par value after the Par Call Dates.
- 7A change of control event combined with a credit rating downgrade would trigger an offer to repurchase the notes at 101% of principal.